"At Radiometer, our vision is to improve global healthcare with reliable, fast and easy diagnoses. We strive hard to meet the needs and even surpass the expectations of our customers. The PeriFlux 6000 tcpO2 standalone system is the latest generation of transcutaneous monitoring and we’re excited to obtain the distribution rights of the device and further expand its position in the market,"says Henrik Schimmell, President and CEO of Radiometer.
In January 2019 Perimed and Radiometer officially announced a partnership around the distribution of Perimed's PeriFlux 6000 tcpO2 stand-alone by Radiometer.
Radiometer has become the exclusive distributor of the PeriFlux 6000 tcpO2 stand alone in United States, France, Germany, United Kingdom, Australia, as well as China and Japan, effective January 1st, 2019.
"Perimed’s mission is to improve the quality of life for people suffering from vascular diseases, by supplying diagnostic instruments in the field of microcirculation and peripheral macrocirculation. We have good products, but our sales capacity is limited. Radiometer’s sales capability and knowledge in tcpO2 is undisputed and we’re excited to have entered into this partnership. We hope this cooperation will lead to improved diagnostic capability in the wound care and hyperbaric sector," says Björn Bakken, President of Perimed.
You can read the full press release here. For further questions please contact your local representative.